Xcout Intel
Pan Cancer T
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Subscribe to see Pan Cancer T’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pan Cancer T at a glance
Pan Cancer T is a biotechnology company headquartered in Netherlands. Xcout tracks 10 named people at Pan Cancer T, including Dr. Rachel Abbott (Chief Executive Officer).
Pan Cancer T leadership
- Dr. Rachel AbbottChief Executive Officer
- Dr. Tom HoldichChief Medical Officer
- Dr. John TchelingerianChairman
- Dr. Dora HammerlVP R&D, Co-Founder
- Dr. Reinout HesselinkVP Process Development
- Lars OttevangerVP, Finance
4 more named people on record for Pan Cancer T, with roles, board committees and tenure — see the full roster →
Pan Cancer T competitors
A few of Pan Cancer T's closest competitors — see the full list of competitors and alternatives →
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
CPTx is a genetic medicines company that develops in vivo CAR-T therapies for cancer treatment. The company utilizes a proprietary single-stranded DNA (ssDNA) platform combined with lipid nanoparticle delivery systems to create scalable, non-viral genetic therapies.
Tiankeya (also known as Beijing TCR Cure Biopharma Technology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in China, with operations in China and the United States. The company focuses on the innovation, development, and clinical translation of engineered T cell and immune cell therapies to treat cancer and solid tumors.
Zelluna is a Norwegian biotechnology company developing T-cell receptor (TCR)-based natural killer (NK) cell therapies for cancer, with a focus on treating solid tumors. Its products are intended for oncology patients, particularly those with cancers that are difficult to treat using existing immunotherapies.
Get Pan Cancer T's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Pan Cancer T in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access